Advertisement

Author's response to: Comment on “The atherogenic index of plasma as a predictor of mortality in patients with COVID-19”

Published:December 19, 2022DOI:https://doi.org/10.1016/j.hrtlng.2022.12.010
      This paper is the response for the letter to the editor named Comment on “The atherogenic index of plasma as a predictor of mortality in patients with COVID-19” by Vasavada et al. (Vasavada A, Llerena-Velastegui J, Vaca-Perez P. Comment on “The atherogenic index of plasma as a predictor of mortality in patients with COVID-19”. Heart Lung. 2022 Aug 29;57:65. doi: 10.1016/j.hrtlng.2022.08.018. Epub ahead of print. PMID: 36081180; PMCID: PMC9420705.)
      Author's response to: Comment on “The atherogenic index of plasma as a predictor of mortality in patients with COVID-19”.
      First of all, we would like to thank you very much for your interest in our article, we are very honored by your kind words and interest in our study.
      • Ö Turgay Yıldırım
      • Ş Kaya
      The atherogenic index of plasma as a predictor of mortality in patients with COVID-19.
      ,
      • Vasavada A
      • Llerena-Velastegui J
      • Vaca-Perez P
      Comment on "The atherogenic index of plasma as a predictor of mortality in patients with COVID-19.".
      We used binary logistic regression analysis because we divided the study population into two groups, the survivor group and the deceased group and compared them. We included the comorbidities such as hypertension, diabetes mellitus, etc. You mentioned that we should also include the patients under statin therapy. We excluded the patients under dyslipidemia treatment because we evaluated the lipid profile at the admission. We thought that if we included these patient, the lipid profile parameters will not be reliable because they will already be lower than expected. The aim of this study was not to evaluate the effect of statin therapy on mortality of COVID-19 patients. Also as far as we know, our study is the first study to define the changes of lipid profile on COVID-19 patients. So our study may guide other scientists to evaluate the effects of statin therapy on these patients.
      As you mentioned, our study population is small. It is because this is a single centered study and we only included the patients admitted at a 3 months of period. COVID-19 pandemia started at March 2020 in our country. We exaluated the patients who admitted to our hospital between 20.03.2020 to 26.05.2020. We wanted to publish our results as soon as possible because we were not familiar with this new virus at that time and every information and data was very valuable. As you stated, it would be better if our study population was larger but we did not want to wait any longer.
      You also stated that we sould mention AIP as a trustworthy and independent value for stratifying multiple cardiometabolic risks in COVID-19 patients. AIP is already a defined risk factor for cardiovascular system diseases.
      • Dobiasova M
      • Frohlich J
      • Sedova M
      • Cheung MC
      • Brown BG
      Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
      • Niroumand S
      • Khajedaluee M
      • Khadem-Rezaiyan M
      • et al.
      Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease.
      • Turgay Yıldırım Ö
      • Akşit E
      • Aydın F
      • Hüseyinoğlu Aydın A
      Evaluation of atherogenic index of plasma levels at hypertensive patients.
      Our aim in this study was to show that AIP is an indicator of COVID-19 mortality independent of cardiovascular diseases. Also as you mentioned ethnicity is important for COVID-19 patients it would be better if we specify the ethnic differences of our patients. Nafilyan et al. conducted their study in England and stated the importance of ethnicity in COVID-19 pandemic and showed that it may define the risk of bad prognosis and mortality.
      • Nafilyan V
      • Islam N
      • Mathur R
      • Ayoubkhani D
      • Banerjee A
      • Glickman M
      • Humberstone B
      • Diamond I
      • Khunti K.
      Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England.
      But our study is conducted in a single center and our city is ethnically mostly homogeneous.

      References

        • Ö Turgay Yıldırım
        • Ş Kaya
        The atherogenic index of plasma as a predictor of mortality in patients with COVID-19.
        Heart Lung. 2021 Mar-Apr; 50: 329-333https://doi.org/10.1016/j.hrtlng.2021.01.016
        • Vasavada A
        • Llerena-Velastegui J
        • Vaca-Perez P
        Comment on "The atherogenic index of plasma as a predictor of mortality in patients with COVID-19.".
        Heart Lung. 2022 Aug 29; 57 (Epub ahead of print. PMID: 36081180; PMCID: PMC9420705): 65https://doi.org/10.1016/j.hrtlng.2022.08.018
        • Dobiasova M
        • Frohlich J
        • Sedova M
        • Cheung MC
        • Brown BG
        Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography.
        J Lipid Res. 2011; 52: 566-571https://doi.org/10.1194/jlr.P011668
        • Niroumand S
        • Khajedaluee M
        • Khadem-Rezaiyan M
        • et al.
        Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease.
        Med J Islam Repub Iran. 2015; 29 (Published 2015 Jul 25): 240
        • Turgay Yıldırım Ö
        • Akşit E
        • Aydın F
        • Hüseyinoğlu Aydın A
        Evaluation of atherogenic index of plasma levels at hypertensive patients.
        ACEM. 2019; 4: 72-75https://doi.org/10.25000/acem.563986
        • Nafilyan V
        • Islam N
        • Mathur R
        • Ayoubkhani D
        • Banerjee A
        • Glickman M
        • Humberstone B
        • Diamond I
        • Khunti K.
        Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England.
        Eur J Epidemiol. 2021 Jun; 36: 605-617https://doi.org/10.1007/s10654-021-00765-1